【1】People without memory loss will be offered an experimental Alzheimer's drug that could stop the development of the condition before dementia symptoms emerge.
【2】Healthy middle-aged people deemed to have a higher risk of developing the condition will be eligible to participate in the trial, which is being run by an NHS trust as part of an international clinical trial aiming to prevent dementia.
【3】The first European participants in the trial, which is recruiting about 1,600 people aged 55 to 80 from around the world, will be screened on Monday by the Surrey and Borders Partnership NHS foundation trust.
【4】Participants from across the UK will be tested to check that they have no memory problems, before being offered a blood test to assess whether they have p-tau217, a biomarker that can predict cognitive decline and the development of Alzheimer's.
【5】Previous research found people with the highest levels of p-tau217 had an estimated 78% chance of developing cognitive impairment within 10 years.Research has also showed that blood tests measuring p-tau217 could identify Alzheimer's disease with up to 95% accuracy.
【6】The phase III trial, called the PrevenTRON study, will investigate whether prescribing a new drug, trontinemab, to participants who have elevated levels of p-tau217 and meet the trial criteria can stop dementia from developing in the first place.
【7】Trontinemab, which was developed by the Swiss pharmaceutical company Roche, attacks amyloid plaques, a toxic protein that builds up in the brain and slows down – and eventually kills – brain cells.It has been hailed as a groundbreaking drug after early research found that it cleared amyloid plaques in nine out of 10 people with early-stage Alzheimer's or mild cognitive development within 28 weeks.
【8】"For decades, research has focused on treating Alzheimer's disease after symptoms appear.PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin," said Prof Ramin Nilforooshan, chief investigator for the trial.The trial is expected to last four to six years.Participants will be randomly assigned to receive either trontinemab or a placebo, and will then be monitored to see how quickly they develop any signs of dementia.
原文出处:The Guardian(Donna Ferguson,2026-09-05)。报道对象为英国 Surrey and Borders Partnership NHS 基金会信托牵头、罗氏(Roche)药物 trontinemab 的 PrevenTRON III 期预防试验。
三、长难句分析(三步拆解法)
Healthy middle-aged people deemed to have a higher risk of developing the condition will be eligible to participate in the trial, which is being run by an NHS trust as part of an international clinical trial aiming to prevent dementia.
主干:Healthy middle-aged people will be eligible to participate in the trial
修饰①:deemed to have a higher risk of developing the condition —— 过去分词短语作后置定语,修饰 people
非限定定语从句:which is being run by an NHS trust —— 修饰 the trial
修饰②:as part of an international clinical trial aiming to prevent dementia —— 介词短语,其中 aiming to … 为现在分词短语修饰 trial
Participants from across the UK will be tested to check that they have no memory problems, before being offered a blood test to assess whether they have p-tau217, a biomarker that can predict cognitive decline and the development of Alzheimer's.
主干:Participants … will be tested
目的状语:to check that they have no memory problems —— 不定式,内含 that 宾语从句
时间状语:before being offered a blood test —— 介词 before + 动名词被动式
目的状语:to assess whether they have p-tau217 —— 内含 whether 宾语从句
同位语 + 定语从句:a biomarker that can predict cognitive decline … —— 同位语解释 p-tau217,后接 that 定语从句
It has been hailed as a groundbreaking drug after early research found that it cleared amyloid plaques in nine out of 10 people with early-stage Alzheimer's or mild cognitive development within 28 weeks, meaning that one of the key characteristics of Alzheimer's was removed.
主干:It has been hailed as a groundbreaking drug
时间状语从句:after early research found that … —— 内含 that 宾语从句(found 的宾语)
宾语从句主干:it cleared amyloid plaques in nine out of 10 people(with early-stage Alzheimer's or mild cognitive development 作定语;within 28 weeks 作时间状语)
结果状语:meaning that one of the key characteristics of Alzheimer's was removed —— 现在分词表结果,内含 that 宾语从句
The phase III trial, called the PrevenTRON study, will investigate whether prescribing a new drug, trontinemab, to participants who have elevated levels of p-tau217 and meet the trial criteria can stop dementia from developing in the first place.
主干:The phase III trial will investigate …(宾语为 whether 从句)
同位语:called the PrevenTRON study —— 过去分词短语说明 trial 名称
宾语从句主干:whether prescribing a new drug, trontinemab, to participants … can stop dementia from developing(动名词 prescribing 作从句主语)
定语从句:who have elevated levels of p-tau217 and meet the trial criteria —— 修饰 participants,并列谓语 have + meet
译文:这项名为 PrevenTRON 的 III 期试验将探究:给 p-tau217 水平升高且符合试验标准的参与者开一种名为 trontinemab 的新药,能否从一开始就阻止痴呆的发生。